Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism

Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · see citing works

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780 · see citing works

Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Que´bec Cardiovascular Study

Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 845 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. A. (2001) · Cited by 732 · see citing works

An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma

Huttunen, J. K., Ehnholm, C., Kinnunen, P. K. J., & Nikkilä, E. A. (1975) · Clinica Chimica Acta · doi:10.1016/0009-8981(75)90055-8 · Cited by 298 · see citing works

Laboratory standardization of a large international clinical trial: the DAIS experience

McGuinness, C., Seccombe, D. W., Frohlich, J. J., Ehnholm, C., Sundvall, J., & Steiner, G. A. (2000) · Clinical Biochemistry · doi:10.1016/s0009-9120(99)00081-8 · Cited by 37 · see citing works

Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS)∗∗This article is dedicated to Dr. David de Bono, Leicester, United Kingdom, who recenlty passed away. Dr. de Bono was the cardiologist member of the Safety and Data Monitoring Board for DAIS. He served with wisdom and quiet valor until its last meeting.

Steiner, G. A., Stewart, D., & Hosking, J. D. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00488-9 · Cited by 25 · see citing works

Lipids and Lipoproteins in Patients With Type 2 Diabetes

Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 755 · see citing works

Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease

Vakkilainen, J., Steiner, G. A., Ansquer, J.-C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., & Taskinen, M. (2003) · Circulation · doi:10.1161/01.cir.0000057982.50167.6e · Cited by 270 · see citing works

Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition

Basu, D., Huggins, L.-A., Scerbo, D. A., Obunike, J. C., Mullick, A. E., Rothenberg, P., Prospero, N. A. D., Eckel, R. H., & Goldberg, I. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311339 · Cited by 163 · see citing works

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

Farnier, M., Freeman, M. W., Macdonell, G., Perevozskaya, I. T., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi231 · Cited by 161 · see citing works

Sensory Neurons and Schwann Cells Respond to Oxidative Stress by Increasing Antioxidant Defense Mechanisms

Vincent, A. M., Kato, K., McLean, L. L., Soules, M. E., & Feldman, E. L. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2235 · Cited by 120 · see citing works

Dyslipidemia in type 2 diabetes

Krauss, R. M., & Siri, P. W. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.004 · Cited by 117 · see citing works

Micronised Fenofibrate

Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 113 · see citing works

Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men — A Nuclear Magnetic Resonance Study

Ikewaki, K., Tohyama, J., Nakata, Y., Wakikawa, T., Kido, T., & Mochizuki, S. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.278 · Cited by 76 · see citing works

How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol

Lim, S. K., Park, Y. M., Sakuma, I., & Koh, K. K. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.127 · Cited by 64 · see citing works

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia

Farnier, M., Roth, E., Gil-Extremera, B., Mendez, G. F., Macdonell, G., Hamlin, C., Perevozskaya, I., Davies, M. J., Kush, D., & Mitchel, Y. B. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.10.031 · Cited by 83 · see citing works

Type 2 diabetes mellitus: a cardiovascular perspective

Varughese, G. I., Tomson, J., & Lip, G. Y. H. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00571.x · Cited by 57 · see citing works

Combination therapy for combined dyslipidemia

Xydakis, A. M., & Ballantyne, C. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02968-5 · Cited by 56 · see citing works

Update on Fenofibrate

Guay, D. R. P. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00098.x · Cited by 45 · see citing works

Polyacrylamide Gradient Gel Electrophoresis of Lipoprotein Subclasses

Warnick, G. R., McNamara, J. R., Boggess, C. N., Clendenen, F., Williams, P. T., & Landolt, C. C. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.005 · Cited by 42 · see citing works

Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp (Ctenopharyngodon idella) fed a high-fat diet

Du, Z., Clouet, P., Degrace, P., Zheng, W., Frøyland, L., Tian, L., & Liu, Y. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508986840 · Cited by 41 · see citing works

Fenofibrate and metabolic syndrome

T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works

α-Lipoic acid as a triglyceride-lowering nutraceutical

Pashaj, A., Xia, M., & Moreau, R. F. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0480 · Cited by 30 · see citing works

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome

Bays, H. E., Shah, A. K., Lin, J., Sisk, C. M., Paolini, J. F., & Maccubbin, D. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.020 · Cited by 25 · see citing works

Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs

KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 24 · see citing works

Treatment of Hypertriglyceridemia With Fibric Acid Derivatives: Impact on Lipid Subfractions and Translation Into a Reduction in Cardiovascular Events

McCullough, P. A., Ahmed, A. B., Zughaib, M. T., Glanz, E. D., & Loreto, M. J. D. (2011) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0619 · Cited by 21 · see citing works

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

Reyes‐Soffer, G., Rondon-Clavo, C., & Ginsberg, H. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.563506 · Cited by 19 · see citing works

The relation of vitamin D status with metabolic syndrome in childhood and adolescence: an update

Challa, A. S., Makariou, S. E., & Siomou, E. C. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0485 · Cited by 18 · see citing works

Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate

Wood, A. C., Aslibekyan, S. W., Borecki, I. B., Hopkins, P. N., Lai, C., Ordovás, J. M., Straka, R. J., Tiwari, H. K., & Arnett, D. K. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328357f6af · Cited by 18 · see citing works

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

Kei, A. A., Liberopoulos, E. N., Tellis, K., Rizzo, M., Elisaf, M., & Tselepis, A. D. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12095 · Cited by 14 · see citing works

The metabolic regulation of fenofibrate is dependent on dietary protein content in male juveniles of Nile tilapia (Oreochromis niloticus)

Ning, L., Liu, Y., Wang, W., Li, Y., Chen, L., & Du, Z. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519001594 · Cited by 13 · see citing works

Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells

Roberts, J. L., He, B., Erickson, A., & Moreau, R. F. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.12.001 · Cited by 12 · see citing works

Vitamin D, parathormone, and insulin resistance in children born large for gestational age

Giapros, V. I., Challa, A. S., Cholevas, V., Evagelidou, E. N., Bairaktari, E. T., & Andronikou, S. K. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0327 · Cited by 11 · see citing works

Acanthosis nigricans, vitamin D, and insulin resistance in obese children and adolescents

Slyper, A. H., Kashmer, L., Huang, W., & Re’em, Y. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0465 · Cited by 11 · see citing works

Comparative cardiometabolic effects of fibrates and omega-3 fatty acids

Han, S. H., Oh, P. C., Lim, S. K., Eckel, R. H., & Koh, K. K. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.223 · Cited by 9 · see citing works

Efficacy and Safety of the Coadministration of Ezetimibe With Fenofibrate in Patients With Mixed Hyperlipidaemia

Farnier, M., Freeman, M. W., & Macdonell, G. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.08.205 · Cited by 9 · see citing works

Efficacy and Safety of Ezetimibe/Simvastatin Co- Administered with Fenofibrate in Mixed Hyperlipidemic Patients with Metabolic Syndrome

Extremera, B. G., Méndez, G., Zakson, M., Meehan, A. G., Shah, A. K., Lin, J., & Mitchel, Y. (2007) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2007.0011 · Cited by 9 · see citing works

Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants

Tsai, A. K., Steffen, B. T., Ordovás, J. M., Straka, R. J., Zhou, X., Hanson, N. Q., Arnett, D. K., & Tsai, M. Y. (2011) · Translational research · doi:10.1016/j.trsl.2011.01.014 · Cited by 7 · see citing works

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate

Wood, A. C., Wojczynski, M. K., Borecki, I. B., Hopkins, P. N., Lai, C., Ordovás, J. M., Straka, R. J., Tsai, M. Y., Tiwari, H. K., & Arnett, D. K. (2014) · Biology · doi:10.3390/biology3030536 · Cited by 3 · see citing works

Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins

Anabtawi, A., Moriarty, P. M., & Miles, J. M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0872-8 · Cited by 3 · see citing works

Comparisons of statistical methods in analyzing clinical data through systematically using historical data

Xu, L., Qu, Y., & Kulkarni, P. M. (2012) · Model Assisted Statistics and Applications · doi:10.3233/mas-2011-0217 · Cited by 2 · see citing works

Diabetic Dyslipidemia

Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_11 · Cited by 2 · see citing works

Lipodysregulation and Type 2 diabetes in TALLYHO/Jng Mice

Mostafa, O. A. (2006)

References

(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs

References

(2005) · Wiley eBooks · doi:10.1002/9780470774663.refs

Precision Medicine for Diabetes and Dyslipidemia

Alexander, E., Cristiano, E., & Miles, J. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_3

Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease

Vakkilainen, J., Steiner, G. A., Ansquer, J.-C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., & Taskinen, M. (2003) · Circulation · doi:10.1161/01.cir.0000057982.50167.6e · Cited by 270 · see citing works

Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial

Tsunoda, F., Asztalos, I. B., Horvath, K. V., Steiner, G. A., Schaefer, E. J., & Asztalos, B. F. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.028 · Cited by 40 · see citing works

EFFECT OF FENOFIBRATE ON LIPID LEVELS OF TYPE 2 DIABETIC PATIENTS WITH DYSLIPIDEMIA

村上, 宏., 玉澤, 直., 大和, 一., 田辺, 壽., 葛西, 伸., 松井, 淳., 管, 静., 小川, 吉., & 須田, 俊. (2004) · Institutional Repositories DataBase (IRDB)

Treating lipid abnormalities in patients with type 2 diabetes mellitus.

Steiner, G. (2001) · American Journal of Cardiology · doi:10.1016/s0002-9149(01)02151-8 · Cited by 34 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 845 · see citing works